Acheuron Hungary Ltd
| Business category 1 | Project Cooperation |
| City ( of main office ) | Szeged, HU, Hungary |
| Address | CsongradSzegedTiszavirag u. 11 |
| Phones | 36-62-409106 |
| Fax | 36-62-409106 |
| Web site | www.acheuron.hu |
| About | The company is a next-generation biology, chemistry informatics and pharmaceutical company that addresses the unmet medical needs of chronic diseases. Services include state-of-the-art informatics, custom chemical synthesis, and screening of herbal and fungal sources of new biologically active materials. Drug discovery strategy of the company includes data mining of information available on the drug target of interest, then in the 2nd stage potentially useful small molecular hits are generated by screening small molecular libraries of synthetics, herbal and fungal extracts. In the 3rd phase, hits from dedicated compound libraries, either synthetic or natural origins, are evaluated for specificity, potential side effects, and efficacy by computational docking experiments carried out with the cognate molecular targets of interest. In the 4th step, best hits are refined to leads by employing medical and computational chemistry means such as molecular modeling and docking the chemical fragment to the target. The 5th step in the drug discovery pipeline includes specificity and efficacy testing by molecular and cellular pharmacological tools and assays. Compliance with these criteria leads eventually to the proof of principle: drug candidates finally are validated in vivo experiments, carried out in conventional animal models of human diseases and proprietary gene manipulated mice mimic the pertinent pathological phenotype of interest. All company employees hold university diplomas and / or Ph. D. degrees in the life sciences and are excellently prepared to complete text-mining from drug patents and the scientific literature. Beside DB building practice and experience, the company has a strong IP portfolio in treating chronic pain and other neuron degeneration and neurological diseases with innovative medicines, either synthesized or purified from non-toxic herbs and fungi. Moreover, the company's proprietary screening technologies have provided new and versatile pain treatment protocols for cerebral palsy and lower back pain ready for human clinical trials. The company has recently discovered alternative uses of existing drugs on the market which have promise for use in pain treatment. For the second-use patent, drugs undergo clinical trials starting from human Phase III. The company is in the process of ranking these drugs by employing proprietary live-cell-based technologies and in vivo animal models of various pain syndromes. |
| Date | 2011 Oct 29, 09:10 |